Skip to Content

Short-Term Risk for Below-Knee Amputation Not Increased With SGLT2i

FRIDAY, Aug. 7, 2020 -- For patients with type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors do not increase the risk for below-knee amputation compared with dipeptidyl peptidase 4 (DPP-4) inhibitors, according to a study published online Aug. 5 in Diabetes Care.

Oriana Hoi Yun Yu, M.D., from the Jewish General Hospital in Montreal, and colleagues conducted a multicenter observational study using administrative health care databases to compare the risk for below-knee amputation with SGLT2 inhibitors versus DPP-4 inhibitors among patients with type 2 diabetes. Data were included for 207,817 incident SGTL2 inhibitor users matched to 207,817 DPP-4 inhibitor users.

The researchers found amputation rates of 1.3 and 1.5 per 1,000 person-years among SGLT2 inhibitor users and DPP-4 inhibitor users, respectively, during a mean exposed follow-up time of 11 months. For below-knee amputations, the adjusted hazard ratio was 0.88 (95 percent confidence interval, 0.71 to 1.09) in association with SGLT2 inhibitor use versus DPP-4 inhibitor use. In stratified analyses by specific SGLT2 inhibitor molecule, similar results were obtained.

"Future studies will be needed to further address whether SGLT2 inhibitor use increases the risk of incident below-knee amputation over the longer term," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Rates of Reamputation High in Patients With Diabetes

TUESDAY, June 15, 2021 -- Nearly four in 10 patients with diabetes who have undergone initial amputations secondary to diabetes will have a reamputation within five years...

Exacerbations Down in Asthma Patients on GLP-1R Agonists for T2D

MONDAY, June 14, 2021 -- For adults with type 2 diabetes and asthma, exacerbation rates are lower for those prescribed glucagon-like peptide-1 receptor (GLP-1R) agonists...

Obesity-Related Outcomes Up for Metabolically Healthy Obese

FRIDAY, June 11, 2021 -- "Metabolically healthy obesity" (MHO) is associated with an increased risk for obesity-related outcomes, including incident diabetes, atherosclerotic...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.